Using Metabolic Biomarkers to Predict Risk for Postpartum Depression
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
Post-Marketing Safety Data for Brexanolone (Zulresso)
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
Single Day CBT-Based Workshops for Mothers with Postpartum Depression
In this randomized controlled trial, a CBT-based workshop for women with PPD led to clinically meaningful reductions in depression and anxiety.
Understanding the Complex Relationship Between Infant Sleep and Maternal Sleep and Mental Health
Changes in maternal sleep and circadian rhythms during pregnancy are associated with infant sleep problems and maternal depression and anxiety.
In Subfertile Women Who Conceive With or Without Assistance, Low Risk of Postpartum Depression
Risk of PPD is low in women who successfully conceive.
Zuranolone for Postpartum Depression: Results from the SKYLARK Study
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
Can Oxytocin Be Used to Treat Postpartum Depressive Symptoms?
Intranasal oxytocin improves mood in postpartum women but has no impact on mood in women with more severe depressive symptoms.
Is Preeclampsia a Risk Factor for Postpartum Psychiatric Illness?
Most, but not all, studies show an association between preeclampsia and increased risk for postpartum psychiatric illness.
Essential Reads: Is PMDD a Risk Factor for Postpartum Depression?
Some, but not all, studies suggest that PMDD is a risk factor for postpartum depression.
Research from the CWMH: Screening for Postpartum Depression, Treatment Engagement, Barriers to Care
Further systematic research on outcomes after postpartum screening is needed to ensure that screening translates into improved clinical outcomes.